February 16sful human tests for first wirelessly controlled drug delivery chipA study in the Feb. 16 online issue of Science Translational Medicine was published that MIT professors and scientists from Microchip Inc. Robert Langer and Michael Cima have in development a microchip provides managed daily doses of an osteoporosis medication that is usually given by injection. This success is based on an idea, the researchers developed some 15 years ago – a programmable, wireless control microchip that could deliver drug in a patient’s body after implantation to create. The study was funded and controlled by microchips.

The team aims to broaden the MICS reach, the latest versions the latest versions only for a distance of a few centimeters. Consistent results in the current study , the team formation of bone in osteoporosis patients implanted with the chip measured and found to be comparable to that in persons by injection. Of teriparatide observed. In addition, the researchers found that the doses administered by implant showed less variation than the doses administered by injection.. Since the chips are programmable, doses can be called remotely triggered by a special frequency a specific frequency Medical Implant Communications Service , or are planned in advance.This Journal of the National Cancer Institute is published by Oxford University Press and with the with the National Cancer Institute. Attribution the journal of the National Cancer Institute offer into of all the coverage. Visiting the Journal online jncicancerspectrum.oxfordjournals.